[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605809":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":73,"collaborators":77,"id":95,"slug":25,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":25,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":25,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"The Affiliated Hospital of Qingdao University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Clostridium butyricum group","EXPERIMENTAL","Oral Clostridium butyricum capsules, Live: take 3 capsules twice daily (bid) for the first 3 months after adenoma resection, then continue with 3 capsules once daily (qd) until 3 years post-resection (each capsule contains ≥6.3 × 10⁶ CFU of Clostridium butyricum).",[13],"Drug: Clostridium butyricum capsules, Live",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Placebo capsules containing corn starch, with identical appearance, weight, and administration method as the study group.",[19],"Other: Control (placebo)",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Clostridium butyricum capsules, Live",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Control (placebo)","Placebo capsules containing corn starch, with identical appearance, weight, and administration method as the treatment group.",[15],[31],{"name":32,"affiliation":5,"role":33},"yanbing Zhou","STUDY_CHAIR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Gan Liu","CONTACT","+86 18866799842","docliu163@163.com",{"name":32,"role":37,"phone":41,"phoneExt":25,"email":42},"+86 0532-82911324","zhouyanbing@qduhospital.cn",[44,60],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"the Affiliated Hospital of QIngdao University","RECRUITING","Qingdao","Shandong","266000","China",{"type":52,"coordinates":53},"Point",[54,55],120.38042,36.06488,{"lat":55,"lon":54},[58,59],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},{"name":32,"role":37,"phone":25,"phoneExt":25,"email":42},{"facility":61,"status":46,"city":62,"state":48,"zip":25,"country":50,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Weifang People's Hospital","Weifang",{"type":52,"coordinates":64},[65,66],119.10194,36.71,{"lat":66,"lon":65},[69],{"name":70,"role":37,"phone":71,"phoneExt":25,"email":72},"Junxi Sun","13573667956","sjx1971@sina.com",{"type":74,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Zhou Yanbing","The Director of the Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University",[78,80,82,84,86,87,89,91,93],{"name":79,"class":6},"Shandong Cancer Hospital and Institute",{"name":81,"class":6},"Yantai Yuhuangding Hospital",{"name":83,"class":6},"Rizhao People's Hospital",{"name":85,"class":6},"Qianfoshan Hospital",{"name":61,"class":6},{"name":88,"class":6},"Dongying People's Hospital",{"name":90,"class":6},"Peking University People's Hospital",{"name":92,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"name":94,"class":6},"The First Affiliated Hospital of Bengbu Medical University","100605809",false,"NCT07167342","The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma","The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma - A Multicenter, Double-blinded, Differential Design, Randomized, Placebo-controlled Study","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* No restriction on sex\n* Boston Bowel Preparation Score (BBPS) ≥ 7 prior to endoscopic procedure\n* Completed endoscopic resection of colorectal adenomas (including cold snare polypectomy, ESD, EMR, etc.) with no residual adenomas or polyps observed endoscopically\n* Histologically confirmed adenomas (including tubular, villous, or tubulovillous types) without malignant transformation\n* Able to take oral medication\n* Signed informed consent\n\nExclusion Criteria:\n\n* Use of probiotics, prebiotics, synbiotics, or antibiotics within 2 weeks prior to enrollment\n* Presence of psychiatric disorders or other conditions preventing compliance with the intervention\n* Dysfunction of vital organs (liver, kidney, heart, etc.) deemed unsuitable for clinical study participation after evaluation\n* Participation in other clinical trials within 3 months prior to enrollment\n* History of gastrointestinal surgery (excluding endoscopic procedures)\n* History of inflammatory bowel disease\n* History of autoimmune diseases\n* Long-term use of aspirin (≥100 mg\u002Fday for over 3 months) or calcium supplements (≥1200 mg\u002Fday for over 3 months)\n* Pregnancy or breastfeeding\n* Previous treatment for colorectal adenomas (including endoscopic or surgical resection)\n* Familial adenomatous polyposis (FAP)","ALL","18 Years","75 Years",{"count":105,"type":106},294,"ESTIMATED","INTERVENTIONAL",[109],"PHASE4","The prevention of recurrence after colorectal adenoma resection remains an urgent medical issue to be addressed. Previous studies have mainly focused on nonsteroidal anti-inflammatory drugs, calcium supplements, and vitamins. The gut microbiota and its metabolic products are believed to play a potential role in the development and progression of colorectal adenomas. Clostridium butyricum, a butyrate-producing probiotic, has not yet been studied for its potential in preventing the recurrence of colorectal adenomas following resection. Therefore, this study, designed as a multicenter, double-blind, placebo-controlled randomized controlled trial, aims to explore evidence-based data on the role of Clostridium butyricum in preventing colorectal adenoma recurrence.",[112,113],"Colorectal Adenoma","Probiotics",[112,115],"Clostridium butyricum","2026-05-22",{"date":118,"type":119},"2026-05-26","ACTUAL",{"date":116,"type":119},{"date":122,"type":106},"2030-04-30",{"name":5,"class":6},2]